Summit Therapeutics plc : Exercise of Options

11 October 2016, 07:02

Source - GNW

Summit Therapeutics plc("Summit" or the "Company")

EXERCISE OF SHARE OPTIONS

Oxford, UK, 11 October 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, announces that, following the exercise of employee share options, the Company has issued 77,500 new ordinary shares of 1p each (the "New Ordinary Shares").

Application has been made for the admission to trading on AIM of the New Ordinary Shares, which will rank pari passu with the Company's existing ordinary shares, and admission is expected to occur on or around 14 October 2016.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 61,800,756. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: Summit Therapeutics plc via Globenewswire

Market Overview

FTSE 350 Risers and Fallers

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. If you would like to change your preferences you may do so by following the instructions here.